DA Davidson cuts Destination XL stock price target on margin pressure

DXLG reported FY2025 Q4 EPS of -$0.10 versus consensus -$0.02 (miss of $0.08) and revenue of $112.1M, slightly below forecasts. DA Davidson lowered its price target to $1.50 from $2.00 but reiterated a Buy; shares trade at $0.49 near a 52-week low of $0.47. Margins deteriorated due to higher markdowns and fixed-cost deleverage; GLP-1 pressure is noted as a headwind. The FullBeauty merger is expected to close in Q2 2025, and pre-market activity showed some investor optimism despite the miss.

Analysis

The merger pathway creates an underappreciated lever: consolidation of SKUs, private‑label assortments and shared distribution can drive 200–400bps of gross margin expansion within 12–24 months if inventory is reallocated away from clearance channels. That dynamic would convert current markdown-driven inventory losses into higher full‑price sell‑through and materially shorten cash conversion cycles, benefiting gross margin and ROIC more than headline sales growth alone.

The primary secular risk—medical weight‑loss adoption—operates on a multi‑year cadence and will be non‑uniform across cohorts. Expect measurable revenue impact concentrated in the next 12–36 months; however, the biggest near‑term earnings swing will come from inventory discipline and SG&A deleverage (quarterly), not immediate TAM collapse. Management’s ability to tighten receipts and slow promotional cadence is therefore a sharper short‑term lever than consumer health trends.

For shareholders the trade is binary: successful integration and SKU rationalization re‑rate the business at low single‑digit EV/EBITDA multiples into mid‑teens margins, while repeated clearance activity forces further dilution or strategic asset sales. Liquidity and float are limited—therefore option structures or small, disciplined equity bets are preferable to large outright positions.

Monitor three operational thresholds as catalysts: (1) sequential improvement in full‑price sell‑through (2) SG&A leverage per store, and (3) disclosed cost synergies from the merger. Any of these meeting management targets should compress implied risk premia quickly; failure to show progress on two of three within six quarters is the clearest route to further downside.

Key Decisions for Investors

• Tactical long (asymmetric, event-driven): Buy DXLG Jan 2026 $1 LEAP calls sized to 1% of portfolio — thesis wins if merger synergies + inventory discipline return EBITDA to 2026/27 runway; target 3x payoff, stop-loss: total premium loss (lottery ticket approach).
• Hedge pair: For a neutral macro hedge, pair the DXLG LEAP long with a short XLY (S&P Consumer Discretionary ETF) position sized 0.5–1% NAV to strip out sector beta during integration risk (12–24 month horizon).
• Downside hedge / momentum short: If next two quarters show continued heavy markdowning and no SG&A improvement, initiate a short DXLG position or buy puts (3–6 month tenor) sized 0.5% NAV — target 50% price decline, stop at 25% adverse move.
• Event‑arb rule: After definitive merger economics are disclosed, treat the spread as a classic arb — go long the combined equity (if accretive and cash‑light) funded by a 0.5–1% short in XRT (retail ETF) to neutralize retail flow risk; require published synergy targets ≥$10m with 18‑month realization before adding material risk.